Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

Kymera’s upsized IPO and 66% gain underscore investors’ continuing appetite for both protein degradation companies and preclinical plays.

The offering comes as key milestones approach for protein degradation companies, one of which has reached the clinic while others — including another newly public company — prepare their initial clinical entries...